DexCom
DXCM
YETI Holdings
YETI
New Fortress Energy
NFE
Dorian LPG
LPG
Collegium Pharmaceutical
COLL
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | ||||||||||
Gross profit | ||||||||||
Operating expense | 129.57%83.06M | 58.99%23.52M | 126.27%21.64M | 213.73%20.8M | 229.30%17.09M | 36.18M | 14.79M | 9.56M | 6.63M | 5.19M |
Selling and administrative expenses | 170.42%22.12M | 111.09%6.32M | 207.31%6.1M | 167.73%5.11M | 255.26%4.59M | --8.18M | --3M | --1.98M | --1.91M | --1.29M |
-General and administrative expense | 170.42%22.12M | 111.09%6.32M | 207.31%6.1M | 167.73%5.11M | 255.26%4.59M | --8.18M | --3M | --1.98M | --1.91M | --1.29M |
Research and development costs | 117.63%60.94M | 45.77%17.2M | 105.05%15.54M | 232.32%15.69M | 220.70%12.5M | --28M | --11.8M | --7.58M | --4.72M | --3.9M |
Operating profit | -129.57%-83.06M | -58.99%-23.52M | -126.27%-21.64M | -213.73%-20.8M | -229.30%-17.09M | -36.18M | -14.79M | -9.56M | -6.63M | -5.19M |
Net non-operating interest income expense | 380.33%12.14M | 157.53%3.54M | 379.32%4.1M | 1,112.22%2.68M | 2,320.00%1.82M | 2.53M | 1.38M | 856K | 221K | 75K |
Non-operating interest income | 380.33%12.14M | 157.53%3.54M | 379.32%4.1M | 1,112.22%2.68M | 2,320.00%1.82M | --2.53M | --1.38M | --856K | --221K | --75K |
Other net income (expense) | -557.47%-7.39M | 0 | -617.48%-7.39M | -1.12M | -94K | -1.03M | ||||
Other non- operating income (expenses) | -557.47%-7.39M | --0 | ---- | ---- | -617.48%-7.39M | ---1.12M | ---94K | ---- | ---- | ---1.03M |
Income before tax | -125.18%-78.31M | -47.86%-19.98M | -101.39%-17.54M | -182.74%-18.12M | -268.84%-22.67M | -34.78M | -13.51M | -8.71M | -6.41M | -6.15M |
Income tax | 0 | 0 | 0 | 0 | 0 | 10K | 6K | 1K | 2K | 1K |
Net income | -125.11%-78.31M | -47.79%-19.98M | -101.37%-17.54M | -182.65%-18.12M | -268.78%-22.67M | -34.79M | -13.52M | -8.71M | -6.41M | -6.15M |
Net income continuous Operations | -125.11%-78.31M | -47.79%-19.98M | -101.37%-17.54M | -182.65%-18.12M | -268.78%-22.67M | ---34.79M | ---13.52M | ---8.71M | ---6.41M | ---6.15M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -125.11%-78.31M | -47.79%-19.98M | -101.37%-17.54M | -182.65%-18.12M | -268.78%-22.67M | -34.79M | -13.52M | -8.71M | -6.41M | -6.15M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -125.11%-78.31M | -47.79%-19.98M | -101.37%-17.54M | -182.65%-18.12M | -268.78%-22.67M | -34.79M | -13.52M | -8.71M | -6.41M | -6.15M |
Basic earnings per share | 83.64%-3.78 | -49.16%-0.57 | -38.90%-0.5 | -541.54%-1.7 | -269.97%-0.94 | -23.1 | -0.3821 | -0.36 | -0.265 | -0.2541 |
Diluted earnings per share | 83.64%-3.78 | -49.16%-0.57 | -38.90%-0.5 | -541.54%-1.7 | -269.97%-0.94 | -23.1 | -0.3821 | -0.36 | -0.265 | -0.2541 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |